East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cevimeline Hydrochloride Capsules, 30 mg. Aurobindo Pharma’s Cevimeline Hydrochloride Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Evoxac® Capsules manufactured by Cosette Pharmaceuticals, Inc.

Cevimeline Hydrochloride Capsules are indicated for:

• The treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome.